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Antibodies to Clq in systemic lupus erythematosus: Characteristics
and relation to Fc1RIIA alleles. Autoantibodies to the collagen-like
region of the first complement component (C1qAB) are found in patients
with systemic lupus erythematosus (SLE), particularly those with renal
disease. In a cohort of 46 SLE patients with diffuse proliferative glomer-
ulonephritis, we found declining C1qAB titers in 77% of treatment
responders and in only 38% of treatment non-responders (P < 0.03). To
further characterize this autoantibody, we tested 240 SLE patients for the
presence of C1qAB. Positive titers were found in 44% of patients with
renal disease and 18% of patients without renal disease ( P < 0.0003).
Analysis of IgU subclass revealed IgG2 C1qAB alone in 34%, IgGi
C1qAB alone in 20%, and both IgGi and IgG2 in 46% of patients. Fewer
than 10% of patients had measurable titers of IgG3 or IgG4 C1qAB. The
pathogenic role of these IgG2-skewed CIqAB may relate to impaired
immune complex clearance by the mononuclear phagocyte system: IgG2
antibodies are efficiently recognized by only one IgG receptor, the H131
allele of FcyRIIa (FcyRIIa-H131). In contrast, FcyRIIa-R131, which is
characterized by minimal IgG2 binding, has recently been associated with
lupus nephritis. In our C1qAB positive patients, the presence of FcyRIIA-
R131 was associated with an increased risk for renal disease. Autoanti-
bodies to Clq may have pathogenic significance in SLE patients with
genetic defects in the ability to clear IgG2 containing immune complexes.
Autoantibodies to the collagen-like region of the first comple-
ment component (C1qAB) have been described in patients with a
variety of diseases characterized by the presence of circulating
immune complexes [1—91. Systemic lupus esythematosus is the
prototypic immune complex disease. In SLE, CIqAB are associ-
ated with proliferative renal disease [3, 4, 10]. Rising titers may
predict an ensuing relapse of nephritis [11].
There are several different mechanisms by which C1qAB may
exert a pathophysiologic role. The autoantibody could act system-
ically to enlarge circulating immune complexes or up-regulate
activation of the classical complement pathway. Alternatively,
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C1qAB may bind to glomerular immune complex deposits and
amplify the potential for complement activation and subsequent
tissue injury; renal deposition of Clq is characteristic of prolifer-
ative lupus nephritis [12]. Several studies have addressed the
subclass distribution of CIqAB [8, 13—15]. While some investiga-
tors have found a predominance of IgG2 CIqAB [8], others have
detected both IgG2 and IgG3 [14, 15]. Still others have noted an
autoantibody subclass distribution similar to that of normal serum
[13].
The qualitative nature of the autoantibody response in the
context of effector cells may determine pathogenic potential.
Among the many phagocyte receptors for immunoglobulin
(FcyR), only one type, FcyRIIa, is capable of binding IgG2
[16—19]. FcyRIIA has two codominantly expressed alleles (R131
and H131) that differ at amino acid position 131, and as a
consequence differ substantially in their ability to bind human
IgG2. No other immunoglobulin subclass exhibits this differential
recognition among FcR variants [16]. FcyRIIa-H131 is the only
human FcyR that recognizes IgG2 efficiently, and optimal IgG2
handling occurs only in the homozygous state [17—20]. In contrast,
the R131 allele, characterized by minimal IgG2 binding, has
recently been associated with lupus nephritis [20, 21]. C1qAB may
thus manifest enhanced pathogenicity in patients with inherited
deficiencies in the removal of IgG2 containing immune com-
plexes. These findings suggest that genetic susceptibility to lupus
nephritis may be related to the impaired handling of potentially
nephritogenic autoantibodies. To examine this possibility, we used
the following approach: we studied the relationship between
C1qAB titers and clinical response to treatment of lupus nephri-
tis; we determined the prevalence of C1qAB in a population of
240 SLE patients; we characterized the CIqAB IgG subclass
distribution; and we analyzed autoantibody associations with renal
disease and serologic markers of disease activity. Our results
reveal an IgG2 C1qAB subclass predominance and a relationship
between FcyRIIA alleles and CIqAB.
METHODS
Study subjects
African American (N = 129) and Caucasian (N = 111) SLE
patients meeting at least four revised ACR criteria for disease
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classification [22], together with ethnically and geographically
similar non-SLE controls, were recruited from the following
collaborating medical centers: Hospital for Special Surgery/Cor-
nell University Medical Center, New York, New York; National
Institutes of Health, Bethesda, Maryland; and SUNY Brooklyn!
Downstate Medical Center, New York, New York. Patients
included previously reported Caucasians and African Americans
[20] in whom sera was available (N = 190), and additional patients
recruited from these centers over the next year. There were 19
men and 221 women. The mean age was 41 12.9 years, and the
mean duration of SLE 11 9.0 years. The mean daily dose of
prednisone was 12.5 mg; 20% of patients were receiving addi-
tional immunosuppressives (cyclophosphamide, azathioprine, or
methotrexate).
Renal disease was defined as the presence of any of the
following manifestations: proteinuria, (> 500 mg/24 hr or 3+),
cellular casts, or renal biopsy diagnostic of glomerulonephritis.
Renal biopsy data were available on 75 patients: 3 patients had
WHO Class II lesions, 16 WHO Class III, 47 WHO Class IV, and
9 WHO Class V. Laboratory values recorded at study entrance
included recent anti-DNA antibody titers, complement levels, and
quantitative or qualitative measurements of proteinuria. Whole
blood and sera were stored at —70°C. Patients were entered into
the study without regard for disease activity.
For the longitudinal study, sera from ethnically heterogeneous
SLE patients (N = 46) with WHO class IV lupus nephritis were
stored at the time of renal biopsy and at one year following
nephritis treatment. Treatment regimens included: (1) i.v. cyclo-
phosphamide monthly for six months followed by every three
months for a minimum of 2½ years (N = 21); (2) i.v. methyipred-
nisolone monthly for a minimum of 12 months to a maximum of
three years (N = 13); and (3) the combination of regimens 1 and
2 (N = 12). A clinical response to treatment was defined by the
presence of all of the following: (1) < 10 RBC/HPF, (2) absence
of cellular casts, (3) < 1 gram of proteinuria, and (4) failure to
double serum creatinine. The effect of treatment assignment on
clinical response has been published elsewhere [23].
Indirect ELISA for C1qAB
Both basic and subclass ELISAs for C1qAB were performed
using a modification of the methods of Wisnieski and Jones [8].
Whole Clq was purified from human plasma by the method of
Tenner, Lesavre and Cooper [241. Ninety-six well microtiter plates
(Immulon 4; Dynatech Laboratories, Chantilly, VA, USA) were
coated with Clq at 10 j.tg/ml in PBS, stored at 4°C overnight, and
blocked prior to use with gelatin. Test sera were diluted 1:50 in
gelatin-PBS containing 0.75 M NaCl (GPBS-5x), and plated in
triplicate. Plates were incubated 60 to 90 minutes at 25° and
washed three times with veronal buffered saline (VBS) containing
0.1% Tween 20 (Sigma Chemicals, St. Louis, MO, USA). An
alkaline phosphatase-conjugated goat anti-human IgG Fc (Jack-
son ImmunoResearch Laboratories, West Grove, PA, USA) was
added for 60 minutes, followed by repeat washings, and the
addition of paranitrophenyl phosphate (Sigma) in a dietheno-
lamine buffer. Color was allowed to develop until dilutions of a
positive standard serum run on each plate met pre-defined values
along the linear portion of its binding curve (specifically, the 1:800
dilution gave an 0D405 of 0.2/well). The upper limit of normal,
based on the mean 5 SD of 30 normals run on three occasions,
was chosen to eliminate false positives and low-level true positives
which would not be detectable in the subclass assay. Sera with
values > 0.17 ODU per well at 1:50 dilution were defined as
positive for C1qAB. A decline in titer was defined by a 50% or
greater drop in ODU, based on interplate variability.
To exclude the possibility that immune complexes contribute to
the Clq binding measured in this assay, we performed experi-
ments with two types of immune complexes (bovine IgG-rabbit
anti-bovine IgG and ciyoglobulinemic sera, IgG-IgM). Immune
complexes of bovine IgG and rabbit anti-bovine IgG were tested
for solid phase Clq binding at 0.15 M, 0.75 M, and1.2 M NaCl. Clq
binding was robust at 0.15 M, undetectable or barely detectable at
0.75 M [< 10% of the positive control serum, which was a
mid-range positive serum from a patient with the hypocomple-
mentemic urticarial vasculitic syndrome (HUVS)] and undetect-
able at 1.2 M NaCl. There was no decrease in binding of average
HUVS serum to Clq at 1.2 M versus 0.75 M NaCl. We also tested
for solid-phase Clq binding using sera from three patients with
cryoglobulinemia, one type II and two type III. The sera were
tested at dilutions of 1:10 and 1:40 with binding simultaneously
measured at 0.15 M and 0.75 M NaCI. In 0.15 M NaCl, there was
measurable Clq binding by IgM-IgG complexes in 1:10 dilution of
these sera which decreased by approximately 50% at a 1:40
dilution. In 0.75 M NaCl, Clq binding decreased by 90% relative
to binding at 0.15 M NaC1 for both dilutions of sera. Concurrently,
Clq binding of an HUVS sera (1:200 and 1:800 dilutions)
decreased by only 50 to 60%, and substantial binding activity
remained at 0.75 M NaCI. These observations argue against
immune complex Fc-mediated binding as a sigificant contributor
to the Clq binding.
ELISA for IgG subclasses of C1qAB
The subclass ELISA was adapted from the method of Wisnieski
and Jones [8]. Each of four 96-well plates (Dynatech) was coated
with triplicate standard dilutions of a single myeloma protein
(IgGi, IgG2, IgG3, or IgG4; The Binding Site, Birmingham, UK),
and incubated five hours at 38 to 42°C to allow adherence to the
plate. The remaining wells were coated with whole Clq(10 jg/ml)
at room temperature, and the plates stored at 4°C overnight. Prior
to use, plates were blocked for two to three hours with GPBS-5x.
Sera were diluted 1:20 in GPBS-5X, plated in triplicate, and
incubated 60 to 90 minutes. After washing three times with VBS
containing 0.1% Tween 20 (Sigma), plates were incubated with
the relevant peroxidase-conjugated polyclonal sheep anti-human
subclass reagent (The Binding Site). In preliminary experiments,
each antibody was titrated to yield a consistent standard curve
over the dilutions of myeloma protein used. There was no
cross-reactivity in subclass recognition within this range. Plates
were developed using o-phenylenediamine (Sigma) with H202 in
a citrate buffer. The reaction was stopped at 30 minutes with 2 N
H2S04, and the OD492 recorded. Results are reported as nano-
grams/well of each subclass extrapolated from the linear portion
of the corresponding myeloma standard curve (linear range: IgGI,
IgG2, IgG4 0.25 to 2.5 /Lg/mI; IgG3 0.03 to 0.25 jtg/ml). High titer
sera were subjected to serial dilution.
Radial immunodiffusion for total serum IgGi and IgG2
Radial immunodifi'usion was performed using pre-prepared
plates containing monospecific antiserum to IgGi or IgG2 (The
Binding Site). Each plate contained both a subclass specific
calibrator and standard control serum. Serum samples (5 j.tl)
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diluted 1:10 in 7% BSA were pipetted into test wells. Diffusion
was allowed to progress for 72 to 96 hours, at which point each
calibrator reached a pre-defined diameter. Precipitin ring diame-
ters of test samples were read to 0.1 mm using an eye piece and
converted to mg/mi of immunoglobulin using established tables.
IgG subclass values were used to calculate percentage of subclass
C1qAB relative to total serum subclass.
Fc'yRIIA genotyping
The method used in our laboratory for FcyRIIA genotyping has
been published previously [25]. Briefly, DNA was isolated from
peripheral blood leukocytes using Puregene reagents (Gentra
Systems, Minneapolis, MN, USA). A 1 kB portion of the FcyRIIA
gene containing exon 4 and 5 was amplified by polymerase chain
reaction in a gene-specific fashion using primers described by
Osborne et al [25]. The PCR products were denatured and
applied to a Hybond-N in duplicate using a Bio-Dot apparatus
(Bio-Rad Laboratories, Hercules, CA, USA). The blots were
probed with allele-specific olignucleotides 3'-end labeled with
digoxigenin, immuno-detected with an alkaline phosphatase-con-
jugated anti-digoxigenin antibody, and visualized with a colormet-
nc substrate system (Boehringer-Manheim, Indianapolis, IN,
USA). In 22 of 22 subjects tested, phenotypes determined by
quantitative flow cytometry were confirmed to be concordant with
genotypes.
Statistical analysis
Comparisons between groups were made using the Chi square,
Mann-Whitney U, Fisher's exact, or i-tests as appropriate. A
probability of less than 0.05 was used to reject the null hypothesis.
Statistical analysis was performed with the aid of the Research
and Methodology Core of the Hospital for Special Surgery.
RESULTS
C1qAB longitudinal study
Sera from SLE patients (N = 46) with diffuse proliferative lupus
nephritis were stored at the time of renal biopsy and at one year
following initiation of nephritis treatment. Thirty-three patients
[clinical responders (N = 17) and non-responders (N = 16)] had
at least one positive test for C1qAB (Fig. 1). Responders and
Table 1. Demographics and laboratory parameters of C1qAB( +) and
C1qAB(—) patients
Dataa C1qAB(+) C1qAB(—) P value
Mean age in yearsb (N = 232) 36.6 13.2 42.9 12.2 0.0004
Mean duration SLE in years 10.2 9.3 11.4 8.8 0.134
(N = 226)% . C3 (N = 186) 52% 32% 0.01% . C4 (N = 169) 52% 23% 0.002
% Anti-DNA + (N = 157) 57% 30%
-
0.001
non-responders did not differ with respect to race, age, serum
creatinine, or degree of quantitative proteinuria at study entry.
Among clinical responders, 77% demonstrated declining C1qAB
titers. In contrast, only 38% of non-responders exhibited signifi-
cant declines in titer (P < 0.03, Fisher's exact test). Non-
responders more often had rising titers after one year of treat-
ment (P = 0.62). There was no significant difference in treatment
regimens between patients with declining C1qAB and those with
rising or unchanged titers (cyclophosphamide containing regi-
mens vs. methylprednisolone alone, P = 0.17). The association
between C1qAB and clinical response to nephritis treatment
suggests that these autoantibodies may play a role in disease
pathogenesis.
C1qAB cross sectional study
To characterize the association between C1qAB and renal
disease in our population and to identify patients for subclass
analysis, we performed a multicenter cross-sectional study on 240
SLE patients. Both renal (N = 139) and non-renal (N = 101)
patients were tested for IgG Cl qAB by indirect ELISA. Overall,
autoantibodies to Clq were found in 33% of patients. CIqAB
were found in 44% of patients with renal disease and 18% of
patients without renal disease, a difference that was highly signif-
icant (, P < 0.0003). Rates of antibody positivity were similar
between African American and Caucasian patients (30% vs. 40%
respectively, P = 0.17). Among all patients with C1qAB (N = 78),
77% had renal manifestations of SLE. The positive predictive
value of C1qAB for the presence of renal disease was therefore
77%, and the negative predictive value 51%.
The demographic and laboratory parameters of the C1qAB
positive and negative patients are summarized in Table 1. Patients
with the autoantibody were younger; they were more likely to be
hypocomplementemic, and to test positive for antibodies to DNA.
The magnitude of proteinuria, graded as I to 4+, was positively
associated with the presence of C1qAB (P < 0.001, Mann
Whitney U). Mean prednisone dose was higher in the group with
C1qAB (20 mg q.d. vs. 8.8 mg q.d., P < 0.001, Mann-Whitney U
test) hut the use of additional immunosuppressives was not
associated with autoantibody positivity. There was no relationship
between SLE disease duration and the presence of C1qAB.
Among patients with renal disease who were positive for
C1qAB (N = 61), biopsy data were available on 41. Two patients
had WHO Class II lesions, 9 had WHO Class III, 26 had WHO
class IV, and 4 had WHO Class V. Therefore, 85% (35 of 41) of
hiopsied patients with C1qAB had focal or diffuse proliferative
glomerulonephritis.
>0.75
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Fig. 1. Correlation of declining C1qAB titers with clinical response to
treatment of DPGN. Clinical response was defined in the Methods section.
A decline in titer was defined as a 50% change in OD units. Responders
(•) had declining C1qAB titers more often than non-responders (LII); P <
0.03.
a A total of 240 patients were tested for C1qAB. Numbers in parenthe-
ses indicate the population on whom information was available. Labora-
One year tories were obtained within three months of testing for C1qAB.
follow-up h Results are expressed as the mean so
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Fig. 2. Subclass distribution of C1qAB. Each symbol (•) represents a
single patient within each subclass. Statistical analysis was performed on
values greater than 2 so above the mean of 30 healthy normals (cutoffs:
IgGi = 12.2 ng; IgG2 = 15.6 ng; IgG3 = 2 ng; IgG4 = 5 ng).
C1qAB subclass distribution
Available sera testing positive for IgG C1qAB (N = 77) from
Caucasian and African American patients in both the cross-
sectional and longitudinal studies were analyzed for C1qAB IgG
subclass distribution. Results were expressed as nglwell of C1qAB
subclass. The predominant IgG subclasses were IgG2 and IgGi
(Fig. 2). Fifty-six patients had C1qAB subclass values greater than
2 SDS above the mean of 30 healthy normals. Of these, 34% of
patients had IgG2 C1qAB only, 20% had IgGi C1qAB only, and
46% had both IgGi and IgG2 C1qAB. Therefore, IgG2 C1qAB
was present in 80% of patients. The percent of patients with IgG2
C1qAB did not differ between African Americans and Caucasians
(80% vs. 82%, respectively). Rare patients had detectable
amounts of IgG4 C1qAB. Despite a tenfold increased sensitivity
of the IgG3 assay, no patient had detectable nanogram quantities
of IgG3 C1qAB.
We considered the possibility that cyciophosphamide therapy
may have altered the C1qAB IgG subclass distributions of our
patients. However, only five patients with detectable C1qAB in
the subclass ELISA were receiving cyciophosphamide therapy.
The remainder were begun on therapy after sera were obtained or
had received remote treatment. Of these five patients, two had
IgGi C1qAB only, and three had both IgGi and IgG2 C1qAB,
arguing that the IgG2 skewing that we observed is not an artifact
of cyciophosphamide treatment.
A subset of sera from patients with IgGi or IgG2 C1qAB (N =
43) were assayed for total serum IgGi and IgG2 levels by radial
immunodiffusion. The mean total serum IgGi was 8.8 4.1
mg/ml; the mean total serum IgG2 was 2.8 1.3 mg/mi. These
levels did not differ between African Americans (IgGi 9.6 3.7
mg/mi; IgG2 3.1 1.6 mg/mI) and Caucasians (IgGi 8.2 4.3
mg/mI; IgG2 2.6 1.1 mg/mi). The mean ratio of G1/G2 (3.8
2.4 mg/mI) was similar to that reported in the literature for disease
free individuals [26]. However, the percentage of IgG2 C1qAB
relative to total IgG2 was significantly greater than the percentage
of IgGi C1qAB relative to total IgGi (0.04 0.06% vs. 0.01
0.02% respectively, P < 0.005, t-test). Thus, in our patient
population the IgG2 component of the autoantibody response to
Clq is disproportionately enriched relative to the overall IgG
subclasss distribution, as no alteration in IgG subclass distribution
was noted.
FcyRIIA genotyping analysis
The R131 allele of FcyRIIA has been associated with lupus
nephritis in African Americans; a parallel association in Cauca-
sians is controversial [20, 21, 27]. FcyRIIa-R131 is linked to
impaired internalization of IgG2 opsonized immune complexes
[16—20]. Given the IgG2 predominance of our C1qAB, we
questioned whether the presence of R131 confers an additional
risk for renal disease in those with known C1qAB. We determined
the FcyRIIA genotypes of 78 SLE patients from the cross-
sectional study who tested positive for C1qAB from whom DNA
was available, and found that 32% of patients were R131 homozy-
gotes, 46% R131/H131 heterozygotes, and 22% H131 homozy-
gotes.
Among Caucasians with C1qAB (N = 41), there were 27%
R131 homozygotes, 46% R131/H131 heterozygotes, and 27%
H131 homozygotes. Renal disease was present in 87% (26 of 30)
of patients with an R131 allele. In contrast, in C1qAB positive
patients homozygous for H131, only 55% had renal disease. In
this group of C1qAB positive Caucasians, the presence of
FcyRIIA-R131 was associated with an increased risk for renal
disease [x2, P = 0.03; odds ratio for risk of nephritis with
R131-containing genotypes 5.4 (95% C.I. 0.9 to 36.3)].
Among African Americans with C1qAB (N = 37), there were
34% R131 homozygotes, 55% R131/H131 heterozygotes, and
16% H131 homozygotes. Renal disease was present in 24 of 31
patients with R131 and 4 of 6 patients homozygous for H131. Due
to the small number of H131 homozygotes, we were unable to
demonstrate an enhanced risk for renal disease among African
Americans with FcyRIIA-R131 versus 11131.
A parallel analysis was performed on patients whose sera tested
positive for antibodies to double stranded DNA within six months
of C1qAB testing (N = 66). Among patients with anti-DNA
antibodies, there was no relationship between the presence of
R131 and the risk for renal disease (P = 0.6 in both African
Americans and Caucasians). These findings were expected given
the predominance of IgGi and IgG3 subclass in antibodies to
DNA reported in the literature [28, 29].
DISCUSSION
In 1971, Agnello et a! [30] first noted the presence of a low
molecular weight reactant in the sera of SLE patients which
possessed binding activity in the solid phase Clq binding assay.
Subsequently, Uwatoko and Mannik [1] confirmed the existence
of monomeric IgG with specificity for the collagen-like region of
Clq. C1qAB has since been described in patients with a variety of
immune mediated diseases including systemic lupus erythemato-
sus (SLE), hypocomplementemic urticarial vasculitic syndrome
(HUVS), idiopathic membranoproliferative nephritis, and rheu-
matoid arthritis [1—9].
The association of C1qAB with proliferative lupus nephritis is
now well established [3, 4, 10, 11]. The mechanisms mediating
autoantibody pathogenicity remain unclear. In the present study,
we initially evaluated the relationship between C1qAB levels and
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clinical response to nephritis treatment. Treatment responders
were more likely to demonstrate declining C1qAB, supporting a
role for these autoantibodies in disease pathogenesis. It has been
proposed that C1qAB may act systemically by up-regulating
activation of the classical complement pathway [31].Alternatively,
CIqAB may act locally within the renal glomerulus to enhance
tissue injury initiated by immune complex deposition. Indeed,
lesions of proliferative lupus nephritis are characterized by prom-
inent deposition of lgG and Clq [12, 32]. Purified C1qAB have
been shown to deposit in mouse glomeruli perfused with cation-
ized immune complexes containing human CIq [33].
Au alternative hypothesis is that the fate of C1qAB bound
immune complexes is partially dependent on the integrity of the
mononuclear phagocyte system. In this model, efficient leukocyte
FcyR function would constitute a prerequisite for the optimal
clearance of such complexes, placing importance on FcyR speci-
ficity and subclass affinity. Human leukocyte receptors for IgG are
diverse in structure and function [16]. There are three families of
FcyR (FcyRI, FcyRII, and FcyRIII), each containing multiple
distinct gcnes and alternative splicing variants. FcyRIIa, the most
ubiquitously expressed FcyR, is present on monocytes, neutro-
phils, eosinophils, basophils, tissue macrophages, endothelial and
dendritic cells. FcyRIIA hears an allelic polymorphism with
functional significance: the two codominantly expressed alleles,
R131 and H131, differ substantially in their ability to ligate human
IgG2. FeyRTla-H131 is the only human FcyR which recognizes
IgG2 efficiently. In contrast, FcyRIIa-R131, characterized by
minimal IgG2 binding, is increased in frequency among patients
with lupus nephritis [20, 21]. Given the preliminary evidence that
CIqAB may demonstrate an IgG2 subclass skewing, we sought to
characterize the C1qAB subclass distribution in our large popu-
lation and examine the relationship between allelic variants of
FcyR and the presence of C1qAB.
Our cross-sectional results are consistent with prior studies
showing a CIqAB prevalence of 30 to 50% among SLE patients
[3, 4]. The relatively low percentage of titers among our renal
patients likely reflects the wide variability in nephritis activity
within this group at the time of testing. C1qAB were more likely
to occur in younger patients, in agreement with the observation of
Siegert et al [34]. This may reflect the tendency for renal disease
to occur early in the course of SLE or the presence of an older
population with remote disease. In our population, CIqAB were
associated with antibodies to DNA and low levels of C3 and C4.
These findings are consistent with laboratory correlates found in
prior studies [3, 4, 35].
The C1qAB in our population were predominantly of IgG2 and
IgGi subclasses. This distribution is consistent with that found by
Wisnieski and Jones in a study characterizing C1qAB in patients
with SLE (N = 13) and hypocomplementemic urticarial vasculitis
(N = 12) 181, but contrasts with the lgG3 and lgG2 predominance
reported by Coremans et al in patients with SLE (N 30) [151.
That this IgG2-skewed autoantibody response occurred despite
normal serum levels of total IgGi and IgG2 demonstrates that it
did not reflect an alteration in overall IgG subclass distribution.
Immune complexes composed of lgG2 subclass and antigen
activate complement less efficiently than complexes composed of
IgG1 or IgG3 and antigen, and arc therefore primarily dependent
on efficient Fey receptor function for adequate internalization by
phagocytes. The R131 allele of FcyRIIA, characterized by mini-
mal IgG2 binding, has recently been associated with SLE nephritis
in African Americans [20]. In contrast, among Caucasian SLE
patients skewing of FeyRI1A alleles was documented in only one
of three studies [20, 21, 27]. Accordingly, we explored the
possibility that allelic variants of Fey receptors may have partic-
ular pathogenetic importance in the setting of CIqAB. Among
Caucasians with C1qAB, the presence of R131 was associated
with an increased risk for renal disease. This contrasts with
previous reports showing a lack of FcyRllA allelic skewing in
Caucasian nephritis patients [20, 27], and suggests that, while not
sufficient to identify Caucasian patients at risk for renal disease,
FcyRIIA-R131 may have predictive value in the setting of patho-
genic autoantibodies. It is possible that the association of R131
with renal disease in a Caucasian SLE population from the
Netherlands [21] may reflect local differences in CIqAB preva-
lence.
Among African American patients with C1qAB, H131 was
extremely uncommon. This is consistent with previous reports
documenting an increased frequency of FcyRIIA-R131 among
African Americans with SLE, and suggests that H131 may serve as
a protective gene for this ethnicity. Due to the scarcity of H131
homozygotes, we were unable to show a significant association
between FcyRIIA-R131 and the presence of renal disease among
African Americans with C1qAB. We cannot exclude the possibil-
ity that C1qAB and other IgG2 autoantibodies are important
contributors to nephritis in this population.
Although few studies have addressed the question of JgG
subclass distribution in the glomeruli of patients with lupus
nephritis [36—39], a recent series suggests that IgG2 may be a
predominant subclass in proliferative lesions [39]. Renal deposi-
tion of IgG2, whether indicative of C1qAB or other autoantibod-
ies, supports the relationship between FcyRIIA genotype and
predisposition to lupus nephritis. Our data suggest a link between
deficiencies in effector cell function and impaired handling of
potentially nephritogenic autoantibodies. We anticipate that lon-
gitudinal studies will reveal definitive relationships between
FcyRIIA alleles and C1qAB.
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